163 related articles for article (PubMed ID: 27610644)
1. Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.
Bahamon BN; Gao F; Danaee H
Arch Pathol Lab Med; 2016 Dec; 140(12):1397-1403. PubMed ID: 27610644
[TBL] [Abstract][Full Text] [Related]
2. Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297.
Arbogast S; Behnke S; Opitz I; Stahel RA; Seifert B; Weder W; Moch H; Soltermann A
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):99-105. PubMed ID: 21030862
[TBL] [Abstract][Full Text] [Related]
3. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology.
Ma D; Baruch D; Shu Y; Yuan K; Sun Z; Ma K; Hoang T; Fu W; Min L; Lan ZS; Wang F; Mull L; He WW
BMC Biotechnol; 2012 Nov; 12():88. PubMed ID: 23171216
[TBL] [Abstract][Full Text] [Related]
4. Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.
Smith DH; Fiehn AM; Fogh L; Christensen IJ; Hansen TP; Stenvang J; Nielsen HJ; Nielsen KV; Hasselby JP; Brünner N; Jensen SS
Sci Rep; 2014 Mar; 4():4313. PubMed ID: 24603753
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
6. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.
Podmaniczky E; Fábián K; Pápay J; Puskás R; Gyulai M; Furák J; Tiszlavicz L; Losonczy G; Tímár J; Moldvay J
Pathol Oncol Res; 2015 Apr; 21(2):423-31. PubMed ID: 25194563
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
8. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
Friboulet L; Barrios-Gonzales D; Commo F; Olaussen KA; Vagner S; Adam J; Goubar A; Dorvault N; Lazar V; Job B; Besse B; Validire P; Girard P; Lacroix L; Hasmats J; Dufour F; André F; Soria JC
Clin Cancer Res; 2011 Sep; 17(17):5562-72. PubMed ID: 21750204
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
11. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
12. [Importance of expression of DNA repair proteins in non-small-cell lung cancer].
Rybárová S; Muri J; Hodorová I; Vecanová J; Benický M; Piovarči D; Janík P; Mihalik J; Mirossay L
Klin Onkol; 2012; 25(5):370-4. PubMed ID: 23102199
[TBL] [Abstract][Full Text] [Related]
13. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
14. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
[TBL] [Abstract][Full Text] [Related]
15. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
16. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
19. Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
Dolled-Filhart M; Locke D; Murphy T; Lynch F; Yearley JH; Frisman D; Pierce R; Weiner R; Wu D; Emancipator K
Arch Pathol Lab Med; 2016 Nov; 140(11):1259-1266. PubMed ID: 27788043
[TBL] [Abstract][Full Text] [Related]
20. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
